90Y-besilesomab (TLX66) / Great Ormond Street Hospital for Children, Telix - LARVOL DELTA

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM) (PRNewswire) - "Telix's extensive theranostic pipeline will be showcased in presentations covering...TLX101 (131I-iodofalan or 131I-IPA) glioblastoma therapy; TLX66 (90Y-besilesomab) bone marrow conditioning therapy; TLX252 (225Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy..."

Clinical data • Glioma

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2024 ➔ Sep 2025 | Trial primary completion date: Oct 2023 ➔ Sep 2025

Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Trial primary completion date: Jun 2023 ➔ Oct 2023

Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Initiation date: Jan 2022 ➔ Apr 2022

Trial initiation date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation